Cargando…

Long-term hydroxychloroquine use in patients with rheumatic conditions and development of SARS-CoV-2 infection: a retrospective cohort study

BACKGROUND: Hydroxychloroquine is one of several agents being evaluated in the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. We aimed to examine whether patients with rheumatological conditions receiving chronic hydroxychloroquine therapy are at less risk of de...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gentry, Chris A, Humphrey, Mary Beth, Thind, Sharanjeet K, Hendrickson, Sage C, Kurdgelashvili, George, Williams, Riley J
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Ltd. 2020
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7505552/ https://www.ncbi.nlm.nih.gov/pubmed/32984847 http://dx.doi.org/10.1016/S2665-9913(20)30305-2

Ejemplares similares

Development of SARS-CoV-2 infection in patients with rheumatic conditions on hydroxychloroquine monotherapy vs. patients without rheumatic conditions: A retrospective, propensity-matched cohort study
por: Gentry, Chris A., et al.
Publicado: (2023)

Characteristics and outcomes of US Veterans at least 65 years of age at high risk of severe SARS-CoV-2 infection with or without receipt of oral antiviral agents()
por: Gentry, Chris A., et al.
Publicado: (2023)

The Effect of Nomenclature Revision of Streptococcus bovis to Streptococcus gallolyticus on Subsequent Colon Cancer Screening
por: Thind, Sharanjeet K, et al.
Publicado: (2021)

Hydroxychloroquine in rheumatic autoimmune disorders and beyond
por: Nirk, Eliise Laura, et al.
Publicado: (2020)

Effect of hydroxychloroquine pre-exposure on infection with SARS-CoV-2 in rheumatic disease patients: a population-based cohort study
por: Jung, Sun-Young, et al.
Publicado: (2021)

Clostridium subterminale septicemia in a patient with esophageal cancer
por: Thind, Sharanjeet K., et al.
Publicado: (2014)

Incidence of blindness in a population of rheumatic patients treated with hydroxychloroquine
por: Singh, Dilpreet K, et al.
Publicado: (2019)

Has the door closed on hydroxychloroquine for SARS-COV-2?
por: Paul, Mical
Publicado: (2021)

Hyperglycémie, hydroxychloroquine et SARS-CoV-2
por: Ilias, Ioannis, et al.
Publicado: (2021)

Mycobacterium neoaurum Bloodstream Infection Associated with a Totally Implanted Subclavian Port in an Adult with Diabetes and History of Colon Cancer
por: Moseley Jr., Jack E., et al.
Publicado: (2020)

Impact of hydroxychloroquine used as DMARD on SARS-CoV-2 tests and infection evolution in a population of 871 patients with inflammatory rheumatic and musculoskeletal diseases
por: Trefond, Ludovic, et al.
Publicado: (2021)

Comment on: Incidence of blindness in a population of rheumatic patients treated with hydroxychloroquine
por: Pareek, Anil, et al.
Publicado: (2019)

Revisiting hydroxychloroquine and chloroquine for patients with chronic immunity-mediated inflammatory rheumatic diseases
por: dos Reis Neto, Edgard Torres, et al.
Publicado: (2020)

Comment on: incidence of blindness in a population of rheumatic patients treated with hydroxychloroquine: reply
por: Singh, Dilpreet K, et al.
Publicado: (2019)

Pharmacological options for Candida albicans Endocarditis at the roadblock with irrecoverable prosthetics and drug interactions: a case report and review of literature
por: Sahra, Syeda, et al.
Publicado: (2023)

Are hydroxychloroquine and chloroquine effective in the treatment of SARS-COV-2 (COVID-19)?
por: Wright, Christopher, et al.
Publicado: (2020)

Hydroxychloroquine: mechanism of action inhibiting SARS-CoV2 entry.
por: Yuan, Zixuan, et al.
Publicado: (2020)

Impact of Hydroxychloroquine on Antibody Responses to the SARS-CoV-2 Coronavirus
por: de Miranda Santos, Isabel Kinney Ferreira, et al.
Publicado: (2020)

First evaluation of hydroxychloroquine recommendations in treating SARS-CoV-2
por: Roussel, Y., et al.
Publicado: (2020)

Shining a light on the evidence for hydroxychloroquine in SARS-CoV-2
por: Ingraham, Nicholas E., et al.
Publicado: (2020)

Uncertain effects of hydroxychloroquine and azithromycin on SARS-Cov-2 viral load
por: Nguyen, Tuan V.
Publicado: (2021)

Interpreting the impact of hydroxychloroquine prophylaxis on SARS-CoV-2 infection
por: Yadav, Reetika Malik, et al.
Publicado: (2021)

Hydroxychloroquine in patients with rheumatic diseases during the COVID-19 pandemic: a letter to clinicians
por: Schreiber, Karen, et al.
Publicado: (2020)

Failure of chronic hydroxychloroquine in preventing severe complications of COVID-19 in patients with rheumatic diseases
por: Pham, Khanh, et al.
Publicado: (2021)

Hydroxychloroquine and QT Prolongation in Older Patients with Rheumatic Diseases: Who is afraid of the Boogeyman? We are not!
por: Castagna, Alberto, et al.
Publicado: (2020)

New Anti SARS-Cov-2 Targets for Quinoline Derivatives Chloroquine and Hydroxychloroquine †
por: Gentile, Davide, et al.
Publicado: (2020)

Hydroxychloroquine Proves Ineffective in Hamsters and Macaques Infected with SARS-CoV-2
por: Rosenke, Kyle, et al.
Publicado: (2020)

Corrigendum: Impact of Hydroxychloroquine on Antibody Responses to the SARS-CoV-2 Coronavirus
por: Santos, Isabel Kinney Ferreira De Miranda, et al.
Publicado: (2020)

Review: Hydroxychloroquine and Chloroquine for Treatment of SARS-CoV-2 (COVID-19)
por: Pastick, Katelyn A, et al.
Publicado: (2020)

Synthesis and evaluation of enantiomers of hydroxychloroquine against SARS-CoV-2 in vitro
por: Ni, Yong, et al.
Publicado: (2022)

Hydroxychloroquine prophylaxis for SARS-CoV-2 infection among healthcare workers
por: Karim, Habib M.R., et al.
Publicado: (2020)

Multimorbidity in rheumatic conditions
por: Radner, Helga
Publicado: (2016)

Latent Rheumatic Conditions
por: Phelan, J. R.
Publicado: (1906)

COVID-19, hydroxychloroquine and sudden cardiac death: implications for clinical practice in patients with rheumatic diseases
por: Raza, Hussain Ahmed, et al.
Publicado: (2021)

Hydroxychloroquine in COVID-19: Potential Mechanism of Action Against SARS-CoV-2
por: Satarker, Sairaj, et al.
Publicado: (2020)

Response to uncertain effect of hydroxychloroquine and azithromycin on SARS-CoV-2 viral load.
por: Gautret, Philippe, et al.
Publicado: (2021)

Hydroxychloroquine/mycophenolate mofetil/prednisone: SARS-CoV-2 infection: case report
Publicado: (2021)

Hydroxychloroquine-mediated inhibition of SARS-CoV-2 entry is attenuated by TMPRSS2
por: Ou, Tianling, et al.
Publicado: (2021)

SARS-CoV-2 Persistent Viral Shedding in the Context of Hydroxychloroquine-Azithromycin Treatment
por: Drancourt, Michel, et al.
Publicado: (2021)

A Simple Bayesian Method for Evaluating Whether Data From Patients With Rheumatic Diseases Who Have Been Under Chronic Hydroxychloroquine Medication Since Before the COVID-19 Outbreak Can Speak to Hydroxychloroquine's Prophylactic Effect Against Infection With SARS-CoV-2
por: Musca, Serban C.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_kit2om6e4jgp1oajjogst7p8c7